Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia
Open Access
- 10 March 2014
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 211 (4), 605-612
- https://doi.org/10.1084/jem.20131033
Abstract
Targeting Csnk1a1 provides a potential therapeutic approach for AML associated with nonmutated Tp53.This publication has 28 references indexed in Scilit:
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- Regulation of Ribosomal Protein S6 Phosphorylation by Casein Kinase 1 and Protein Phosphatase 1Online Journal of Public Health Informatics, 2011
- CKIα ablation highlights a critical role for p53 in invasiveness controlNature, 2011
- CK1α Plays a Central Role in Mediating MDM2 Control of p53 and E2F-1 Protein StabilityOnline Journal of Public Health Informatics, 2009
- Proteomic and Genetic Approaches Identify Syk as an AML TargetCancer Cell, 2009
- Casein kinase 1α governs antigen-receptor-induced NF-κB activation and human lymphoma cell survivalNature, 2008
- Modeling the Initiation and Progression of Human Acute Leukemia in MiceScience, 2007
- Casein kinase 1 γ couples Wnt receptor activation to cytoplasmic signal transductionNature, 2005
- Regulation of p53-MDMX Interaction by Casein Kinase 1 AlphaMolecular and Cellular Biology, 2005
- Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformationThe EMBO Journal, 2001